The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial ...

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...

Prostaglandin analogues, such as latanoprost and bimatoprost, are the go-to therapies for glaucoma therapy. They continue to ...

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million ...

Patient awareness of glaucoma differs markedly depending on urban and rural locations and the patient population, and that awareness or lack thereof impacts diagnosis, treatment, ...

Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...